Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Elodie Modave"'
Autor:
Bruce A. Littlefield, Elodie Modave, Amy Weaver, Bram Boeckx, Diether Lambrechts, Agnieszka Wozniak, Patrick Schöffski
Publikováno v:
Clinical Cancer Research. 27:3106-3115
Purpose:A randomized phase III study evaluated the efficacy of eribulin versus dacarbazine in patients with advanced liposarcoma and leiomyosarcoma. Improved overall survival (OS) led to approval of eribulin for liposarcoma, but not for leiomyosarcom
Autor:
Patrick Schöffski, Hans Gelderblom, Elodie Modave, Jean-Yves Blay, Judith V.M.G. Bovée, Che-Jui Lee, Diether Lambrechts, Jozef Sufliarsky, Agnieszka Wozniak, Tom van Wezel, Raf Sciot, Maria Debiec-Rychter, Bram Boeckx
Publikováno v:
Clinical Cancer Research, 27(24), 6737-6748. AMER ASSOC CANCER RESEARCH
Purpose: The European Organization for Research and Treatment of Cancer (EORTC) clinical phase II trial 90101 “CREATE” showed high antitumor activity of crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK)/ROS1, in patients with advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::883fc9b638545a34589047cb951cd737
https://lirias.kuleuven.be/handle/123456789/681918
https://lirias.kuleuven.be/handle/123456789/681918
Autor:
Diether Lambrechts, Maria Debiec-Rychter, Bram Boeckx, Jean-Yves Blay, Patrick Schöffski, Agnieszka Wozniak, Elodie Modave, Silvia Stacchiotti, Piotr Rutkowski, Che-Jui Lee, Raf Sciot
Publikováno v:
Cancers, Vol 13, Iss 6057, p 6057 (2021)
Cancers
Cancers; Volume 13; Issue 23; Pages: 6057
Cancers
Cancers; Volume 13; Issue 23; Pages: 6057
Simple Summary Clear cell sarcoma (CCSA) is a rare subtype of soft tissue sarcoma characterized by EWSR1 rearrangement and subsequent MET upregulation. The European Organisation for Research and Treatment of Cancer 90101 phase II trial evaluated the
Autor:
Bram Boecks, Bruce A. Littlefield, Amy Weaver, Elodie Modave, Patrick Schöffski, Agnieszka Wozniak, Diether Lambrechts
Publikováno v:
Cancer Research. 80:4280-4280
Background. The recent randomized phase 3 trial Eisai Study 309 evaluated efficacy of eribulin (ERI) compared to dacarbazine (DTIC) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS). Improved overall survival (OS) in ERI-treated patients led to
Autor:
Diether Lambrechts, Maria Debiec-Rychter, Elodie Modave, Jozef Sufliarsky, Che-Jui Lee, Bram Boeckx, Agnieszka Wozniak, Raf Sciot, Patrick Schöffski, Jean-Yves Blay, Hans Gelderblom
Publikováno v:
Cancer Research. 80:794-794
About 50% of inflammatory myofibroblastic tumors (IMFTs) harbor rearrangements of anaplastic lymphoma kinase (ALK), the most common driver in this rare tumor. EORTC 90101 “CREATE” is so far the only prospective, disease-specific phase II clinical